New combo therapy ‘effective first line in advanced renal cancer’
The first results of the CheckMate 9ER trial show a good response rate and improved survival, researchers say
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
A checkpoint inhibitor partnered with a targeted chemotherapy agent could be a new first-line option for patients with advanced renal cell carcinoma, a leading oncologist says.
The first results of the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib showed improved survival over 18 months compared with the standard of care, sunitinib, said Dr Toni Choueiri, from the Dana-Farber Cancer Institute and Harvard Medical School, Boston, US.
Dr Choueiri told the European Society for Medical Oncology (ESMO) virtual congress 2020 that the results with combination therapy were “statistically significant and clinically meaningful”.
